Division of Gastroenterology and Hepatology

Medicine & Life Sciences

1. Taiwan 100%
2. Colorectal Neoplasms 99%
3. Hepatocellular Carcinoma 98%
4. Helicobacter pylori 96%
5. Chronic Hepatitis B 72%
6. Neoplasms 71%
7. Stomach 67%
8. Chronic Hepatitis C 56%
9. Stomach Neoplasms 50%
10. Therapeutics 48%
11. Apoptosis 44%
12. Liver Cirrhosis 42%
13. Liver 35%
14. Carcinoma 34%
15. Non-alcoholic Fatty Liver Disease 33%
16. Colonoscopy 32%
17. Interferons 32%
18. Proteins 31%
19. Hepacivirus 30%
20. Colonic Neoplasms 28%
21. Fatty Liver 28%
22. Adenocarcinoma 27%
23. Fibrosis 27%
24. Duodenal Ulcer 26%
25. Confidence Intervals 26%
26. cytolethal distending toxin 25%
27. Hepatitis B virus 25%
28. Pancreatic Neoplasms 25%
29. Helicobacter Infections 25%
30. 15,16-dihydrotanshinone I 24%
31. Endoscopic Mucosal Resection 24%
32. Serum 24%
33. Intussusception 24%
34. Ulcer 23%
35. Odds Ratio 23%
36. Sorafenib 23%
37. Liver Diseases 22%
38. Antiviral Agents 22%
39. Neoplastic Stem Cells 21%
40. Population 21%
41. ErbB Receptors 21%
42. velpatasvir 21%
43. Recurrence 20%
44. Raman Spectrum Analysis 20%
45. Systematic Reviews 20%
46. lycium barbarum polysaccharide 20%
47. Neoplasm Metastasis 19%
48. evodiamine 19%
49. Survival 19%
50. Chromosome Segregation 19%
51. Catenins 19%
52. Inflammation 19%
53. Cetuximab 19%
54. Drug Therapy 19%
55. Hepatitis 19%
56. Alanine Transaminase 19%
57. Hydroxymethylglutaryl-CoA Reductase Inhibitors 19%
58. Hepatitis B 19%
59. Cohort Studies 19%
60. Peptic Ulcer 18%
61. Pylorus 18%
62. Metaplasia 18%
63. Cellular Apoptosis Susceptibility Protein 18%
64. Radiofrequency Ablation 18%
65. Sofosbuvir 18%
66. Liver Neoplasms 17%
67. Mucous Membrane 17%
68. Meta-Analysis 17%
69. Gastritis 17%
70. Lipopolysaccharides 17%
71. Growth 17%
72. Safety 17%
73. glucose-regulated proteins 17%
74. lipoteichoic acid 16%
75. Pancreatitis 16%
76. ovatodiolide 16%
77. Gastrointestinal Diseases 16%
78. Sustained Virologic Response 16%
79. Heme Oxygenase-1 16%
80. Fluorouracil 16%
81. Cell Proliferation 16%
82. Digestive System Endoscopy 16%
83. Evodia 16%
84. Cholesterol 16%
85. Biomarkers 15%
86. Campylobacter jejuni 15%
87. Alcoholic Liver Diseases 15%
88. Reactive Oxygen Species 15%
89. Randomized Controlled Trials 15%
90. Extracellular Signal-Regulated MAP Kinases 15%
91. Propensity Score 15%
92. Cell Line 14%
93. Iron 14%
94. Gastrointestinal Microbiome 14%
95. Phosphotransferases 14%
96. Hepatitis B Surface Antigens 14%
97. Nanoparticles 14%
98. Prostatic Neoplasms 14%
99. Nitric Oxide 14%
100. entecavir 14%